" class="no-js "lang="en-US"> Louise Modis - Medtech Alert
Saturday, August 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Louise Modis

Louise Modis

About Louise Modis

Drug discovery leader with expertise in immunology.

Related Story

Industry News

 Mogrify and Astellas Announce Collaboration to Conduct Research on in Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss | Pharmtech Focus

Mogrify and Astellas Announce Collaboration to Conduct Research on in Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss

July 5 2022

Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of […]

Appointments

 Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer | Pharmtech Focus

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer

October 5 2021

Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming […]